immune response and fighting brain cancer with gene therapy abbie hunt november 10, 2009

14
Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Upload: logan-lane

Post on 11-Jan-2016

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Immune Response and Fighting Brain Cancer

with Gene Therapy

Abbie Hunt

November 10, 2009

Page 2: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Overview

Glioblastoma multiforme (GBM) Dendritic Cells (DC) Fms-like tyrosine kinase 3 ligand (Flt3L) Toll-like receptors (TLR) Bone-marrow derived DCs (BMDC) High-mobility-group box 1 (HMGB1)

Page 3: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Cell lines, etc.

Challengers Ad-TK Ad-Flt3L Ad0

Returning Champions GL26 GL261 B16-F10 LLc1

Page 4: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Mice!

Female C57BL/6 MyD88-/-

TLR4-/-

WT Chimeric

WT and GFP+/+

WT and TLR2-/-

http://brainwindows.files.wordpress.com/2008/10/image-gfp-mouse-crop-copy.jpg

Page 5: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Glioma Models

GL26 GL261 B16-F10

Ad0 Ad-Flt3L + Ad0 Ad-TK + Ad0 Ad-Flt3L + Ad-TK

GCV

Saline

Rechallenged

Page 6: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

T cells necessary in tumor regression

Page 7: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

DCs come from bone marrow

Page 8: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

TLR2 expression by BMDC necessary in tumor regression

Page 9: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

HMGB1 mediates TLR2-dependent glioma tumor regression

Increased levels of HMGB1 from GL26 treated with Ad-TK+GCV in vitro

Increased serum levels in mice Blocked with glycyrrhizin or specific anti-

HMGB1 antibodies

Page 10: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

HMGB1 released from tumor cells with Ad-TK+GCV, chemotherapy, or radiation therapy

Page 11: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Ad-TK(+GCV) + Ad-Flt3L = Survival and Increased HMGB1

Page 12: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

Recap

T cells necessary in tumor regression DCs come from bone marrow TLR2 expression by BMDC necessary in t.r. HMGB1 mediates TLR2-dependent glioma t.r. HMGB1 released from tumor cells with Ad-

TK+GCV, chemotherapy, or radiation therapy Ad-TK (+GCV) and Ad-Flt3L therapy results

in GL261 and B16-F10 tumor regression and increased HMGB1 levels

Page 13: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009
Page 14: Immune Response and Fighting Brain Cancer with Gene Therapy Abbie Hunt November 10, 2009

References 1. Curtin J.F., Liu N., Candolfi M., et al. 2009. HMB1 Mediate

Endogenous TLR2 Activation and Brain Tumor Regression. PLoS Medicine. 6(1): 84-104.

2. Southgate T., Kroeger K.M., Liu C., Lowenstein P.R. (2008). Gene transfer into meural cells in vivo using adenoviral vectors. Published online at Wiley Interscience. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659706/ Accessed 11/4/09.

3. Sandmair A., Vapalahti M., Yla-Herttuala S. (2000). Adenovirus-Mediated Herpes Simplex Thymidine Kinase Gene Therapy for Brain Tumors. Cancer Gene Therapy: Past Achievements and Future Challenges. Plenum Publishers, New York. 163-170.

4. Stevenson, P. Immunological Memory. The Australian Naturopathic Network. Revised 5/18/2002. Available online at http://www.ann.com.au/MedSci/immunolo.htm Accessed 11/3/09.

5. Multitudes of Wikipedia pages